nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—kidney cancer—sarcoma	0.704	1	CtDrD
Everolimus—CYP3A4—Thiotepa—sarcoma	0.0232	0.458	CbGbCtD
Everolimus—CYP3A4—Mitoxantrone—sarcoma	0.00998	0.197	CbGbCtD
Everolimus—CYP3A4—Vincristine—sarcoma	0.00687	0.136	CbGbCtD
Everolimus—CYP3A4—Etoposide—sarcoma	0.00629	0.124	CbGbCtD
Everolimus—MTOR—leg—sarcoma	0.00595	0.108	CbGeAlD
Everolimus—MTOR—forelimb—sarcoma	0.0059	0.107	CbGeAlD
Everolimus—MTOR—hindlimb—sarcoma	0.00531	0.0965	CbGeAlD
Everolimus—MTOR—appendage—sarcoma	0.00456	0.0828	CbGeAlD
Everolimus—CYP3A4—Doxorubicin—sarcoma	0.00429	0.0848	CbGbCtD
Everolimus—MTOR—mammary gland—sarcoma	0.00222	0.0403	CbGeAlD
Everolimus—FKBP1A—mammary gland—sarcoma	0.00199	0.0362	CbGeAlD
Everolimus—MTOR—myometrium—sarcoma	0.00157	0.0286	CbGeAlD
Everolimus—MTOR—embryo—sarcoma	0.00151	0.0275	CbGeAlD
Everolimus—MTOR—seminal vesicle—sarcoma	0.00142	0.0258	CbGeAlD
Everolimus—FKBP1A—myometrium—sarcoma	0.00141	0.0257	CbGeAlD
Everolimus—MTOR—hematopoietic system—sarcoma	0.00135	0.0245	CbGeAlD
Everolimus—MTOR—connective tissue—sarcoma	0.0013	0.0236	CbGeAlD
Everolimus—FKBP1A—seminal vesicle—sarcoma	0.00128	0.0232	CbGeAlD
Everolimus—FKBP1A—hematopoietic system—sarcoma	0.00121	0.0221	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—sarcoma	0.00119	0.0216	CbGeAlD
Everolimus—MTOR—skin of body—sarcoma	0.00117	0.0213	CbGeAlD
Everolimus—FKBP1A—connective tissue—sarcoma	0.00117	0.0213	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—sarcoma	0.00107	0.0194	CbGeAlD
Everolimus—FKBP1A—skin of body—sarcoma	0.00106	0.0192	CbGeAlD
Everolimus—MTOR—uterus—sarcoma	0.00102	0.0185	CbGeAlD
Everolimus—MTOR—lymphoid tissue—sarcoma	0.000951	0.0173	CbGeAlD
Everolimus—FKBP1A—cardiac atrium—sarcoma	0.000922	0.0168	CbGeAlD
Everolimus—FKBP1A—uterus—sarcoma	0.000917	0.0167	CbGeAlD
Everolimus—MTOR—tendon—sarcoma	0.000894	0.0162	CbGeAlD
Everolimus—MTOR—bone marrow—sarcoma	0.000866	0.0157	CbGeAlD
Everolimus—FKBP1A—lymphoid tissue—sarcoma	0.000855	0.0155	CbGeAlD
Everolimus—FKBP1A—tendon—sarcoma	0.000804	0.0146	CbGeAlD
Everolimus—FKBP1A—bone marrow—sarcoma	0.000779	0.0142	CbGeAlD
Everolimus—MTOR—testis—sarcoma	0.00074	0.0135	CbGeAlD
Everolimus—MTOR—liver—sarcoma	0.0007	0.0127	CbGeAlD
Everolimus—FKBP1A—testis—sarcoma	0.000666	0.0121	CbGeAlD
Everolimus—FKBP1A—liver—sarcoma	0.000629	0.0114	CbGeAlD
Everolimus—MTOR—lymph node—sarcoma	0.000536	0.00975	CbGeAlD
Everolimus—FKBP1A—lymph node—sarcoma	0.000482	0.00877	CbGeAlD
Everolimus—CYP3A4—hematopoietic system—sarcoma	0.000397	0.00722	CbGeAlD
Everolimus—CYP3A4—liver—sarcoma	0.000206	0.00374	CbGeAlD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	8.42e-05	0.00113	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—HRAS—sarcoma	8.42e-05	0.00113	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—HRAS—sarcoma	8.34e-05	0.00112	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—JUN—sarcoma	8.26e-05	0.00111	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—SRC—sarcoma	8.2e-05	0.0011	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—JUN—sarcoma	8.18e-05	0.0011	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—HRAS—sarcoma	8.12e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—HRAS—sarcoma	8.12e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—MDM2—sarcoma	8.11e-05	0.00109	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TLE1—sarcoma	8.08e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—SRC—sarcoma	8.06e-05	0.00109	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PLCG1—sarcoma	8e-05	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—KRAS—sarcoma	7.99e-05	0.00108	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—KRAS—sarcoma	7.94e-05	0.00107	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—NRAS—sarcoma	7.89e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PTPRC—sarcoma	7.85e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—sarcoma	7.77e-05	0.00105	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PLCG1—sarcoma	7.68e-05	0.00104	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PLCG1—sarcoma	7.65e-05	0.00103	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—sarcoma	7.64e-05	0.00103	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—JUN—sarcoma	7.62e-05	0.00103	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—ATF1—sarcoma	7.6e-05	0.00102	CbGpPWpGaD
Everolimus—Alanine aminotransferase increased—Doxorubicin—sarcoma	7.59e-05	0.000652	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KIT—sarcoma	7.58e-05	0.00102	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—sarcoma	7.56e-05	0.00102	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—NRAS—sarcoma	7.55e-05	0.00102	CbGpPWpGaD
Everolimus—Neutropenia—Epirubicin—sarcoma	7.52e-05	0.000646	CcSEcCtD
Everolimus—Dysuria—Epirubicin—sarcoma	7.52e-05	0.000646	CcSEcCtD
Everolimus—Dizziness—Thiotepa—sarcoma	7.51e-05	0.000645	CcSEcCtD
Everolimus—Abdominal distension—Doxorubicin—sarcoma	7.49e-05	0.000643	CcSEcCtD
Everolimus—Upper respiratory tract infection—Epirubicin—sarcoma	7.47e-05	0.000642	CcSEcCtD
Everolimus—Dysphagia—Doxorubicin—sarcoma	7.44e-05	0.000639	CcSEcCtD
Everolimus—Influenza—Doxorubicin—sarcoma	7.44e-05	0.000639	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—NRAS—sarcoma	7.43e-05	0.001	CbGpPWpGaD
Everolimus—Pollakiuria—Epirubicin—sarcoma	7.42e-05	0.000638	CcSEcCtD
Everolimus—Hypersensitivity—Vincristine—sarcoma	7.42e-05	0.000637	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—SRC—sarcoma	7.37e-05	0.000994	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CXCR4—sarcoma	7.35e-05	0.00099	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—SRC—sarcoma	7.34e-05	0.000989	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—SRC—sarcoma	7.34e-05	0.000989	CbGpPWpGaD
Everolimus—Paraesthesia—Etoposide—sarcoma	7.32e-05	0.000629	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HRAS—sarcoma	7.31e-05	0.000984	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—HRAS—sarcoma	7.31e-05	0.000984	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—SRC—sarcoma	7.3e-05	0.000984	CbGpPWpGaD
Everolimus—Pancreatitis—Doxorubicin—sarcoma	7.29e-05	0.000626	CcSEcCtD
Everolimus—Weight decreased—Epirubicin—sarcoma	7.27e-05	0.000625	CcSEcCtD
Everolimus—Dyspnoea—Etoposide—sarcoma	7.27e-05	0.000625	CcSEcCtD
Everolimus—Hyperglycaemia—Epirubicin—sarcoma	7.25e-05	0.000623	CcSEcCtD
Everolimus—Somnolence—Etoposide—sarcoma	7.25e-05	0.000623	CcSEcCtD
Everolimus—Angina pectoris—Doxorubicin—sarcoma	7.24e-05	0.000622	CcSEcCtD
Everolimus—Hypersensitivity—Mitoxantrone—sarcoma	7.22e-05	0.00062	CcSEcCtD
Everolimus—Asthenia—Vincristine—sarcoma	7.22e-05	0.00062	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—CREB1—sarcoma	7.22e-05	0.000973	CbGpPWpGaD
Everolimus—Vomiting—Thiotepa—sarcoma	7.22e-05	0.00062	CcSEcCtD
Everolimus—Pneumonia—Epirubicin—sarcoma	7.21e-05	0.000619	CcSEcCtD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—HRAS—sarcoma	7.2e-05	0.00097	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—sarcoma	7.19e-05	0.000968	CbGpPWpGaD
Everolimus—Infestation NOS—Epirubicin—sarcoma	7.17e-05	0.000616	CcSEcCtD
Everolimus—Infestation—Epirubicin—sarcoma	7.17e-05	0.000616	CcSEcCtD
Everolimus—Vomiting—Dactinomycin—sarcoma	7.16e-05	0.000615	CcSEcCtD
Everolimus—Rash—Thiotepa—sarcoma	7.16e-05	0.000615	CcSEcCtD
Everolimus—Bronchitis—Doxorubicin—sarcoma	7.15e-05	0.000614	CcSEcCtD
Everolimus—Dermatitis—Thiotepa—sarcoma	7.15e-05	0.000614	CcSEcCtD
Everolimus—Headache—Thiotepa—sarcoma	7.11e-05	0.000611	CcSEcCtD
Everolimus—Rash—Dactinomycin—sarcoma	7.1e-05	0.00061	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—NRAS—sarcoma	7.09e-05	0.000956	CbGpPWpGaD
Everolimus—Decreased appetite—Etoposide—sarcoma	7.09e-05	0.000609	CcSEcCtD
Everolimus—Pancytopenia—Doxorubicin—sarcoma	7.06e-05	0.000607	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—NRAS—sarcoma	7.06e-05	0.000951	CbGpPWpGaD
Everolimus—Renal failure—Epirubicin—sarcoma	7.04e-05	0.000605	CcSEcCtD
Everolimus—Gastrointestinal disorder—Etoposide—sarcoma	7.04e-05	0.000605	CcSEcCtD
Everolimus—Asthenia—Mitoxantrone—sarcoma	7.03e-05	0.000604	CcSEcCtD
Everolimus—Fatigue—Etoposide—sarcoma	7.03e-05	0.000604	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—NRAS—sarcoma	7.03e-05	0.000946	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—NRAS—sarcoma	6.99e-05	0.000942	CbGpPWpGaD
Everolimus—Jaundice—Epirubicin—sarcoma	6.99e-05	0.0006	CcSEcCtD
Everolimus—Stomatitis—Epirubicin—sarcoma	6.99e-05	0.0006	CcSEcCtD
Everolimus—Constipation—Etoposide—sarcoma	6.97e-05	0.000599	CcSEcCtD
Everolimus—Pain—Etoposide—sarcoma	6.97e-05	0.000599	CcSEcCtD
Everolimus—Urinary tract infection—Epirubicin—sarcoma	6.97e-05	0.000598	CcSEcCtD
Everolimus—Conjunctivitis—Epirubicin—sarcoma	6.97e-05	0.000598	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MYC—sarcoma	6.96e-05	0.000937	CbGpPWpGaD
Everolimus—Neutropenia—Doxorubicin—sarcoma	6.95e-05	0.000597	CcSEcCtD
Everolimus—Dysuria—Doxorubicin—sarcoma	6.95e-05	0.000597	CcSEcCtD
Everolimus—Upper respiratory tract infection—Doxorubicin—sarcoma	6.91e-05	0.000594	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—NRAS—sarcoma	6.89e-05	0.000928	CbGpPWpGaD
Everolimus—Diarrhoea—Vincristine—sarcoma	6.89e-05	0.000592	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—sarcoma	6.88e-05	0.000926	CbGpPWpGaD
Everolimus—Pollakiuria—Doxorubicin—sarcoma	6.87e-05	0.00059	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—SRC—sarcoma	6.84e-05	0.000921	CbGpPWpGaD
Everolimus—CYP3A4—Tryptophan metabolism—MDM2—sarcoma	6.83e-05	0.000921	CbGpPWpGaD
Everolimus—Haematuria—Epirubicin—sarcoma	6.83e-05	0.000587	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—VEGFC—sarcoma	6.82e-05	0.000918	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—sarcoma	6.8e-05	0.000917	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—HRAS—sarcoma	6.79e-05	0.000915	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KRAS—sarcoma	6.79e-05	0.000915	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Epirubicin—sarcoma	6.78e-05	0.000582	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—SRC—sarcoma	6.78e-05	0.000913	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—sarcoma	6.77e-05	0.000912	CbGpPWpGaD
Everolimus—Epistaxis—Epirubicin—sarcoma	6.76e-05	0.000581	CcSEcCtD
Everolimus—MTOR—Signaling by Insulin receptor—HRAS—sarcoma	6.75e-05	0.000909	CbGpPWpGaD
Everolimus—Nausea—Thiotepa—sarcoma	6.74e-05	0.000579	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—sarcoma	6.73e-05	0.000578	CcSEcCtD
Everolimus—Sinusitis—Epirubicin—sarcoma	6.72e-05	0.000578	CcSEcCtD
Everolimus—Feeling abnormal—Etoposide—sarcoma	6.72e-05	0.000577	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—SRC—sarcoma	6.72e-05	0.000905	CbGpPWpGaD
Everolimus—Hyperglycaemia—Doxorubicin—sarcoma	6.71e-05	0.000576	CcSEcCtD
Everolimus—Diarrhoea—Mitoxantrone—sarcoma	6.71e-05	0.000576	CcSEcCtD
Everolimus—Nausea—Dactinomycin—sarcoma	6.69e-05	0.000575	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—SRC—sarcoma	6.69e-05	0.000901	CbGpPWpGaD
Everolimus—Pneumonia—Doxorubicin—sarcoma	6.67e-05	0.000573	CcSEcCtD
Everolimus—Gastrointestinal pain—Etoposide—sarcoma	6.67e-05	0.000573	CcSEcCtD
Everolimus—Dizziness—Vincristine—sarcoma	6.66e-05	0.000572	CcSEcCtD
Everolimus—Infestation—Doxorubicin—sarcoma	6.63e-05	0.00057	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—sarcoma	6.63e-05	0.00057	CcSEcCtD
Everolimus—MTOR—Immune System—CD34—sarcoma	6.59e-05	0.000887	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—NRAS—sarcoma	6.58e-05	0.000886	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—NRAS—sarcoma	6.58e-05	0.000886	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—NRAS—sarcoma	6.58e-05	0.000886	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—NRAS—sarcoma	6.52e-05	0.000878	CbGpPWpGaD
Everolimus—Renal failure—Doxorubicin—sarcoma	6.52e-05	0.00056	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—KRAS—sarcoma	6.5e-05	0.000875	CbGpPWpGaD
Everolimus—MTOR—Disease—TLE1—sarcoma	6.49e-05	0.000874	CbGpPWpGaD
Everolimus—Haemoglobin—Epirubicin—sarcoma	6.47e-05	0.000555	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—EGFR—sarcoma	6.46e-05	0.000871	CbGpPWpGaD
Everolimus—Stomatitis—Doxorubicin—sarcoma	6.46e-05	0.000555	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—sarcoma	6.46e-05	0.000555	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—NRAS—sarcoma	6.46e-05	0.00087	CbGpPWpGaD
Everolimus—Rhinitis—Epirubicin—sarcoma	6.45e-05	0.000554	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—sarcoma	6.45e-05	0.000554	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—sarcoma	6.45e-05	0.000554	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—sarcoma	6.45e-05	0.000554	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—sarcoma	6.45e-05	0.000554	CcSEcCtD
Everolimus—Haemorrhage—Epirubicin—sarcoma	6.43e-05	0.000553	CcSEcCtD
Everolimus—Hepatitis—Epirubicin—sarcoma	6.43e-05	0.000553	CcSEcCtD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—sarcoma	6.43e-05	0.000866	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—sarcoma	6.43e-05	0.000866	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—NRAS—sarcoma	6.43e-05	0.000866	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—KRAS—sarcoma	6.43e-05	0.000866	CbGpPWpGaD
Everolimus—Hypoaesthesia—Epirubicin—sarcoma	6.4e-05	0.00055	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—EGFR—sarcoma	6.4e-05	0.000862	CbGpPWpGaD
Everolimus—Vomiting—Vincristine—sarcoma	6.4e-05	0.00055	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB4—KRAS—sarcoma	6.39e-05	0.000861	CbGpPWpGaD
Everolimus—Pharyngitis—Epirubicin—sarcoma	6.38e-05	0.000549	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—EGFR—sarcoma	6.37e-05	0.000858	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—MDM2—sarcoma	6.37e-05	0.000858	CbGpPWpGaD
Everolimus—Urinary tract disorder—Epirubicin—sarcoma	6.35e-05	0.000546	CcSEcCtD
Everolimus—Rash—Vincristine—sarcoma	6.35e-05	0.000545	CcSEcCtD
Everolimus—Dermatitis—Vincristine—sarcoma	6.34e-05	0.000545	CcSEcCtD
Everolimus—Oedema peripheral—Epirubicin—sarcoma	6.34e-05	0.000544	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—sarcoma	6.32e-05	0.000543	CcSEcCtD
Everolimus—Connective tissue disorder—Epirubicin—sarcoma	6.32e-05	0.000543	CcSEcCtD
Everolimus—Urethral disorder—Epirubicin—sarcoma	6.31e-05	0.000542	CcSEcCtD
Everolimus—Headache—Vincristine—sarcoma	6.31e-05	0.000542	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—sarcoma	6.28e-05	0.000846	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Doxorubicin—sarcoma	6.27e-05	0.000539	CcSEcCtD
Everolimus—Epistaxis—Doxorubicin—sarcoma	6.25e-05	0.000537	CcSEcCtD
Everolimus—Vomiting—Mitoxantrone—sarcoma	6.23e-05	0.000535	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—sarcoma	6.22e-05	0.000534	CcSEcCtD
Everolimus—Rash—Mitoxantrone—sarcoma	6.18e-05	0.000531	CcSEcCtD
Everolimus—Dermatitis—Mitoxantrone—sarcoma	6.17e-05	0.00053	CcSEcCtD
Everolimus—Headache—Mitoxantrone—sarcoma	6.14e-05	0.000528	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—KRAS—sarcoma	6.11e-05	0.000823	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—NRAS—sarcoma	6.09e-05	0.00082	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—KRAS—sarcoma	6.08e-05	0.000819	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KRAS—sarcoma	6.08e-05	0.000819	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—SRC—sarcoma	6.06e-05	0.000816	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KRAS—sarcoma	6.05e-05	0.000815	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KRAS—sarcoma	6.02e-05	0.000811	CbGpPWpGaD
Everolimus—Eye disorder—Epirubicin—sarcoma	6.01e-05	0.000516	CcSEcCtD
Everolimus—Hypersensitivity—Etoposide—sarcoma	6.01e-05	0.000516	CcSEcCtD
Everolimus—MTOR—DAP12 interactions—EGFR—sarcoma	5.99e-05	0.000807	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—sarcoma	5.99e-05	0.000807	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—sarcoma	5.99e-05	0.000807	CbGpPWpGaD
Everolimus—Haemoglobin—Doxorubicin—sarcoma	5.98e-05	0.000514	CcSEcCtD
Everolimus—Nausea—Vincristine—sarcoma	5.98e-05	0.000514	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—MDM2—sarcoma	5.97e-05	0.000805	CbGpPWpGaD
Everolimus—Flushing—Epirubicin—sarcoma	5.97e-05	0.000513	CcSEcCtD
Everolimus—Cardiac disorder—Epirubicin—sarcoma	5.97e-05	0.000513	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—sarcoma	5.97e-05	0.000513	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—sarcoma	5.95e-05	0.000511	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—sarcoma	5.95e-05	0.000511	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—EGFR—sarcoma	5.94e-05	0.0008	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KRAS—sarcoma	5.93e-05	0.000799	CbGpPWpGaD
Everolimus—Hypoaesthesia—Doxorubicin—sarcoma	5.92e-05	0.000509	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—sarcoma	5.91e-05	0.000508	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—sarcoma	5.89e-05	0.000793	CbGpPWpGaD
Everolimus—Urinary tract disorder—Doxorubicin—sarcoma	5.88e-05	0.000505	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—sarcoma	5.86e-05	0.000504	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—EGFR—sarcoma	5.86e-05	0.000789	CbGpPWpGaD
Everolimus—MTOR—Disease—NPM1—sarcoma	5.85e-05	0.000789	CbGpPWpGaD
Everolimus—Asthenia—Etoposide—sarcoma	5.85e-05	0.000503	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—sarcoma	5.85e-05	0.000503	CcSEcCtD
Everolimus—Angiopathy—Epirubicin—sarcoma	5.84e-05	0.000501	CcSEcCtD
Everolimus—Urethral disorder—Doxorubicin—sarcoma	5.83e-05	0.000501	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—NRAS—sarcoma	5.83e-05	0.000785	CbGpPWpGaD
Everolimus—Nausea—Mitoxantrone—sarcoma	5.82e-05	0.0005	CcSEcCtD
Everolimus—Immune system disorder—Epirubicin—sarcoma	5.81e-05	0.000499	CcSEcCtD
Everolimus—Mediastinal disorder—Epirubicin—sarcoma	5.8e-05	0.000498	CcSEcCtD
Everolimus—Chills—Epirubicin—sarcoma	5.77e-05	0.000496	CcSEcCtD
Everolimus—MTOR—Signaling by SCF-KIT—HRAS—sarcoma	5.77e-05	0.000778	CbGpPWpGaD
Everolimus—Pruritus—Etoposide—sarcoma	5.77e-05	0.000496	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—sarcoma	5.71e-05	0.00077	CbGpPWpGaD
Everolimus—Alopecia—Epirubicin—sarcoma	5.68e-05	0.000488	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FOXO1—sarcoma	5.68e-05	0.000765	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—HRAS—sarcoma	5.68e-05	0.000765	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—PDGFRB—sarcoma	5.67e-05	0.000763	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KRAS—sarcoma	5.66e-05	0.000763	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KRAS—sarcoma	5.66e-05	0.000763	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KRAS—sarcoma	5.66e-05	0.000763	CbGpPWpGaD
Everolimus—Mental disorder—Epirubicin—sarcoma	5.64e-05	0.000484	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—KRAS—sarcoma	5.61e-05	0.000756	CbGpPWpGaD
Everolimus—Malnutrition—Epirubicin—sarcoma	5.6e-05	0.000481	CcSEcCtD
Everolimus—Erythema—Epirubicin—sarcoma	5.6e-05	0.000481	CcSEcCtD
Everolimus—MTOR—Innate Immune System—PDGFRA—sarcoma	5.58e-05	0.000752	CbGpPWpGaD
Everolimus—Diarrhoea—Etoposide—sarcoma	5.58e-05	0.000479	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—sarcoma	5.56e-05	0.000478	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—KRAS—sarcoma	5.56e-05	0.000749	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—sarcoma	5.55e-05	0.000747	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KRAS—sarcoma	5.54e-05	0.000746	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—JUN—sarcoma	5.54e-05	0.000746	CbGpPWpGaD
Everolimus—Flushing—Doxorubicin—sarcoma	5.52e-05	0.000475	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—sarcoma	5.52e-05	0.000475	CcSEcCtD
Everolimus—MTOR—Downstream signaling of activated FGFR—HRAS—sarcoma	5.52e-05	0.000744	CbGpPWpGaD
Everolimus—Flatulence—Epirubicin—sarcoma	5.52e-05	0.000474	CcSEcCtD
Everolimus—Dysgeusia—Epirubicin—sarcoma	5.48e-05	0.000471	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FOXO1—sarcoma	5.45e-05	0.000734	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FLT1—sarcoma	5.45e-05	0.000734	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PDGFRB—sarcoma	5.44e-05	0.000733	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—HRAS—sarcoma	5.43e-05	0.000732	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FOXO1—sarcoma	5.43e-05	0.000731	CbGpPWpGaD
Everolimus—FKBP1A—Disease—PDGFRB—sarcoma	5.42e-05	0.00073	CbGpPWpGaD
Everolimus—Back pain—Epirubicin—sarcoma	5.42e-05	0.000465	CcSEcCtD
Everolimus—Angiopathy—Doxorubicin—sarcoma	5.4e-05	0.000464	CcSEcCtD
Everolimus—Dizziness—Etoposide—sarcoma	5.39e-05	0.000463	CcSEcCtD
Everolimus—Muscle spasms—Epirubicin—sarcoma	5.38e-05	0.000463	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—sarcoma	5.38e-05	0.000462	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—sarcoma	5.36e-05	0.000461	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PLCG1—sarcoma	5.36e-05	0.000722	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—PDGFRA—sarcoma	5.36e-05	0.000722	CbGpPWpGaD
Everolimus—Chills—Doxorubicin—sarcoma	5.34e-05	0.000459	CcSEcCtD
Everolimus—FKBP1A—Disease—PDGFRA—sarcoma	5.33e-05	0.000719	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—sarcoma	5.31e-05	0.000715	CbGpPWpGaD
Everolimus—Vision blurred—Epirubicin—sarcoma	5.28e-05	0.000453	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—sarcoma	5.26e-05	0.000452	CcSEcCtD
Everolimus—MTOR—B Cell Activation—KRAS—sarcoma	5.24e-05	0.000706	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—HRAS—sarcoma	5.22e-05	0.000703	CbGpPWpGaD
Everolimus—Mental disorder—Doxorubicin—sarcoma	5.21e-05	0.000448	CcSEcCtD
Everolimus—Ill-defined disorder—Epirubicin—sarcoma	5.2e-05	0.000446	CcSEcCtD
Everolimus—MTOR—Downstream signal transduction—HRAS—sarcoma	5.19e-05	0.000699	CbGpPWpGaD
Everolimus—Vomiting—Etoposide—sarcoma	5.18e-05	0.000445	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—sarcoma	5.18e-05	0.000445	CcSEcCtD
Everolimus—Erythema—Doxorubicin—sarcoma	5.18e-05	0.000445	CcSEcCtD
Everolimus—Anaemia—Epirubicin—sarcoma	5.18e-05	0.000445	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—HRAS—sarcoma	5.16e-05	0.000696	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—HRAS—sarcoma	5.16e-05	0.000696	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CXCR4—sarcoma	5.15e-05	0.000693	CbGpPWpGaD
Everolimus—Agitation—Epirubicin—sarcoma	5.15e-05	0.000442	CcSEcCtD
Everolimus—Rash—Etoposide—sarcoma	5.14e-05	0.000442	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—HRAS—sarcoma	5.14e-05	0.000692	CbGpPWpGaD
Everolimus—Dermatitis—Etoposide—sarcoma	5.14e-05	0.000441	CcSEcCtD
Everolimus—MTOR—DAP12 signaling—HRAS—sarcoma	5.11e-05	0.000689	CbGpPWpGaD
Everolimus—Headache—Etoposide—sarcoma	5.11e-05	0.000439	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—sarcoma	5.11e-05	0.000439	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—ATF1—sarcoma	5.09e-05	0.000686	CbGpPWpGaD
Everolimus—Dysgeusia—Doxorubicin—sarcoma	5.07e-05	0.000436	CcSEcCtD
Everolimus—MTOR—Disease—ENO2—sarcoma	5.07e-05	0.000683	CbGpPWpGaD
Everolimus—Malaise—Epirubicin—sarcoma	5.05e-05	0.000434	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—HRAS—sarcoma	5.04e-05	0.000679	CbGpPWpGaD
Everolimus—Syncope—Epirubicin—sarcoma	5.02e-05	0.000431	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KRAS—sarcoma	5.01e-05	0.000675	CbGpPWpGaD
Everolimus—Leukopenia—Epirubicin—sarcoma	5.01e-05	0.000431	CcSEcCtD
Everolimus—Back pain—Doxorubicin—sarcoma	5.01e-05	0.000431	CcSEcCtD
Everolimus—Muscle spasms—Doxorubicin—sarcoma	4.98e-05	0.000428	CcSEcCtD
Everolimus—Palpitations—Epirubicin—sarcoma	4.95e-05	0.000425	CcSEcCtD
Everolimus—Loss of consciousness—Epirubicin—sarcoma	4.92e-05	0.000423	CcSEcCtD
Everolimus—Cough—Epirubicin—sarcoma	4.89e-05	0.00042	CcSEcCtD
Everolimus—Vision blurred—Doxorubicin—sarcoma	4.88e-05	0.00042	CcSEcCtD
Everolimus—Convulsion—Epirubicin—sarcoma	4.85e-05	0.000417	CcSEcCtD
Everolimus—Nausea—Etoposide—sarcoma	4.84e-05	0.000416	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—sarcoma	4.84e-05	0.000651	CbGpPWpGaD
Everolimus—Hypertension—Epirubicin—sarcoma	4.83e-05	0.000415	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR in disease—HRAS—sarcoma	4.81e-05	0.000648	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—HRAS—sarcoma	4.81e-05	0.000648	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—HRAS—sarcoma	4.81e-05	0.000648	CbGpPWpGaD
Everolimus—Ill-defined disorder—Doxorubicin—sarcoma	4.81e-05	0.000413	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—sarcoma	4.79e-05	0.000411	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—HRAS—sarcoma	4.77e-05	0.000642	CbGpPWpGaD
Everolimus—Myalgia—Epirubicin—sarcoma	4.77e-05	0.00041	CcSEcCtD
Everolimus—Chest pain—Epirubicin—sarcoma	4.77e-05	0.00041	CcSEcCtD
Everolimus—Arthralgia—Epirubicin—sarcoma	4.77e-05	0.00041	CcSEcCtD
Everolimus—MTOR—Immune System—PTPRC—sarcoma	4.76e-05	0.000642	CbGpPWpGaD
Everolimus—Agitation—Doxorubicin—sarcoma	4.76e-05	0.000409	CcSEcCtD
Everolimus—Anxiety—Epirubicin—sarcoma	4.75e-05	0.000408	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	4.73e-05	0.000407	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—HRAS—sarcoma	4.73e-05	0.000637	CbGpPWpGaD
Everolimus—Discomfort—Epirubicin—sarcoma	4.71e-05	0.000405	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—HRAS—sarcoma	4.71e-05	0.000634	CbGpPWpGaD
Everolimus—Malaise—Doxorubicin—sarcoma	4.67e-05	0.000401	CcSEcCtD
Everolimus—Dry mouth—Epirubicin—sarcoma	4.66e-05	0.000401	CcSEcCtD
Everolimus—MTOR—Immune System—PLCG1—sarcoma	4.66e-05	0.000628	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—SRC—sarcoma	4.66e-05	0.000627	CbGpPWpGaD
Everolimus—Syncope—Doxorubicin—sarcoma	4.65e-05	0.000399	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—sarcoma	4.64e-05	0.000398	CcSEcCtD
Everolimus—Palpitations—Doxorubicin—sarcoma	4.58e-05	0.000393	CcSEcCtD
Everolimus—Oedema—Epirubicin—sarcoma	4.57e-05	0.000393	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—sarcoma	4.55e-05	0.000391	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—TLE1—sarcoma	4.54e-05	0.000612	CbGpPWpGaD
Everolimus—Infection—Epirubicin—sarcoma	4.54e-05	0.00039	CcSEcCtD
Everolimus—Cough—Doxorubicin—sarcoma	4.52e-05	0.000388	CcSEcCtD
Everolimus—Shock—Epirubicin—sarcoma	4.5e-05	0.000386	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—sarcoma	4.49e-05	0.000386	CcSEcCtD
Everolimus—Nervous system disorder—Epirubicin—sarcoma	4.48e-05	0.000385	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—NRAS—sarcoma	4.48e-05	0.000604	CbGpPWpGaD
Everolimus—Thrombocytopenia—Epirubicin—sarcoma	4.47e-05	0.000384	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—sarcoma	4.47e-05	0.000384	CcSEcCtD
Everolimus—Tachycardia—Epirubicin—sarcoma	4.46e-05	0.000383	CcSEcCtD
Everolimus—MTOR—B Cell Activation—HRAS—sarcoma	4.45e-05	0.0006	CbGpPWpGaD
Everolimus—Skin disorder—Epirubicin—sarcoma	4.44e-05	0.000381	CcSEcCtD
Everolimus—MTOR—Immune System—ATF1—sarcoma	4.43e-05	0.000596	CbGpPWpGaD
Everolimus—Hyperhidrosis—Epirubicin—sarcoma	4.42e-05	0.00038	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—sarcoma	4.41e-05	0.000379	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—sarcoma	4.41e-05	0.000379	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—sarcoma	4.41e-05	0.000379	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—sarcoma	4.4e-05	0.000378	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	4.38e-05	0.000376	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—sarcoma	4.36e-05	0.000374	CcSEcCtD
Everolimus—Anorexia—Epirubicin—sarcoma	4.36e-05	0.000374	CcSEcCtD
Everolimus—MTOR—Innate Immune System—KIT—sarcoma	4.33e-05	0.000583	CbGpPWpGaD
Everolimus—Dry mouth—Doxorubicin—sarcoma	4.31e-05	0.000371	CcSEcCtD
Everolimus—MTOR—Disease—PLCG1—sarcoma	4.3e-05	0.00058	CbGpPWpGaD
Everolimus—Hypotension—Epirubicin—sarcoma	4.27e-05	0.000367	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—HRAS—sarcoma	4.26e-05	0.000574	CbGpPWpGaD
Everolimus—Oedema—Doxorubicin—sarcoma	4.23e-05	0.000363	CcSEcCtD
Everolimus—Infection—Doxorubicin—sarcoma	4.2e-05	0.000361	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Epirubicin—sarcoma	4.16e-05	0.000358	CcSEcCtD
Everolimus—Shock—Doxorubicin—sarcoma	4.16e-05	0.000357	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—KIT—sarcoma	4.15e-05	0.00056	CbGpPWpGaD
Everolimus—Nervous system disorder—Doxorubicin—sarcoma	4.15e-05	0.000356	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—sarcoma	4.14e-05	0.000356	CcSEcCtD
Everolimus—FKBP1A—Disease—KIT—sarcoma	4.14e-05	0.000557	CbGpPWpGaD
Everolimus—MTOR—Disease—CXCR4—sarcoma	4.13e-05	0.000557	CbGpPWpGaD
Everolimus—Insomnia—Epirubicin—sarcoma	4.13e-05	0.000355	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—sarcoma	4.13e-05	0.000355	CcSEcCtD
Everolimus—MTOR—Innate Immune System—CREB1—sarcoma	4.12e-05	0.000555	CbGpPWpGaD
Everolimus—Skin disorder—Doxorubicin—sarcoma	4.11e-05	0.000353	CcSEcCtD
Everolimus—Paraesthesia—Epirubicin—sarcoma	4.1e-05	0.000353	CcSEcCtD
Everolimus—Hyperhidrosis—Doxorubicin—sarcoma	4.09e-05	0.000351	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—EGFR—sarcoma	4.08e-05	0.00055	CbGpPWpGaD
Everolimus—Dyspnoea—Epirubicin—sarcoma	4.07e-05	0.00035	CcSEcCtD
Everolimus—Somnolence—Epirubicin—sarcoma	4.06e-05	0.000349	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—sarcoma	4.03e-05	0.000346	CcSEcCtD
Everolimus—Dyspepsia—Epirubicin—sarcoma	4.02e-05	0.000346	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—IGF1R—sarcoma	3.99e-05	0.000538	CbGpPWpGaD
Everolimus—Decreased appetite—Epirubicin—sarcoma	3.97e-05	0.000341	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—CREB1—sarcoma	3.95e-05	0.000533	CbGpPWpGaD
Everolimus—Hypotension—Doxorubicin—sarcoma	3.95e-05	0.000339	CcSEcCtD
Everolimus—Gastrointestinal disorder—Epirubicin—sarcoma	3.95e-05	0.000339	CcSEcCtD
Everolimus—Fatigue—Epirubicin—sarcoma	3.94e-05	0.000339	CcSEcCtD
Everolimus—FKBP1A—Disease—CREB1—sarcoma	3.94e-05	0.00053	CbGpPWpGaD
Everolimus—Pain—Epirubicin—sarcoma	3.91e-05	0.000336	CcSEcCtD
Everolimus—Constipation—Epirubicin—sarcoma	3.91e-05	0.000336	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KRAS—sarcoma	3.86e-05	0.000519	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Doxorubicin—sarcoma	3.85e-05	0.000331	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—VEGFC—sarcoma	3.83e-05	0.000517	CbGpPWpGaD
Everolimus—Insomnia—Doxorubicin—sarcoma	3.82e-05	0.000329	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FOXO1—sarcoma	3.8e-05	0.000512	CbGpPWpGaD
Everolimus—Paraesthesia—Doxorubicin—sarcoma	3.8e-05	0.000326	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PDGFRB—sarcoma	3.79e-05	0.000511	CbGpPWpGaD
Everolimus—Dyspnoea—Doxorubicin—sarcoma	3.77e-05	0.000324	CcSEcCtD
Everolimus—Feeling abnormal—Epirubicin—sarcoma	3.77e-05	0.000324	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—sarcoma	3.76e-05	0.000323	CcSEcCtD
Everolimus—Gastrointestinal pain—Epirubicin—sarcoma	3.74e-05	0.000321	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PDGFRA—sarcoma	3.74e-05	0.000503	CbGpPWpGaD
Everolimus—Dyspepsia—Doxorubicin—sarcoma	3.72e-05	0.00032	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—sarcoma	3.68e-05	0.000316	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—sarcoma	3.65e-05	0.000492	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Doxorubicin—sarcoma	3.65e-05	0.000314	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—sarcoma	3.65e-05	0.000313	CcSEcCtD
Everolimus—Constipation—Doxorubicin—sarcoma	3.62e-05	0.000311	CcSEcCtD
Everolimus—Pain—Doxorubicin—sarcoma	3.62e-05	0.000311	CcSEcCtD
Everolimus—Abdominal pain—Epirubicin—sarcoma	3.61e-05	0.00031	CcSEcCtD
Everolimus—Body temperature increased—Epirubicin—sarcoma	3.61e-05	0.00031	CcSEcCtD
Everolimus—Feeling abnormal—Doxorubicin—sarcoma	3.48e-05	0.000299	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—sarcoma	3.46e-05	0.000297	CcSEcCtD
Everolimus—MTOR—Innate Immune System—MDM2—sarcoma	3.41e-05	0.000459	CbGpPWpGaD
Everolimus—Hypersensitivity—Epirubicin—sarcoma	3.37e-05	0.000289	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—sarcoma	3.34e-05	0.000287	CcSEcCtD
Everolimus—Abdominal pain—Doxorubicin—sarcoma	3.34e-05	0.000287	CcSEcCtD
Everolimus—MTOR—Immune System—FOXO1—sarcoma	3.31e-05	0.000445	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDGFRB—sarcoma	3.3e-05	0.000445	CbGpPWpGaD
Everolimus—Asthenia—Epirubicin—sarcoma	3.28e-05	0.000282	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—HRAS—sarcoma	3.28e-05	0.000442	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—MDM2—sarcoma	3.27e-05	0.000441	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MDM2—sarcoma	3.26e-05	0.000439	CbGpPWpGaD
Everolimus—MTOR—Immune System—PDGFRA—sarcoma	3.25e-05	0.000438	CbGpPWpGaD
Everolimus—Pruritus—Epirubicin—sarcoma	3.23e-05	0.000278	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—KDR—sarcoma	3.14e-05	0.000424	CbGpPWpGaD
Everolimus—Diarrhoea—Epirubicin—sarcoma	3.13e-05	0.000269	CcSEcCtD
Everolimus—Hypersensitivity—Doxorubicin—sarcoma	3.12e-05	0.000268	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—FLT1—sarcoma	3.07e-05	0.000413	CbGpPWpGaD
Everolimus—MTOR—Disease—FOXO1—sarcoma	3.05e-05	0.000411	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFRB—sarcoma	3.05e-05	0.000411	CbGpPWpGaD
Everolimus—Asthenia—Doxorubicin—sarcoma	3.03e-05	0.000261	CcSEcCtD
Everolimus—Dizziness—Epirubicin—sarcoma	3.02e-05	0.00026	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PLCG1—sarcoma	3.01e-05	0.000406	CbGpPWpGaD
Everolimus—MTOR—Disease—PDGFRA—sarcoma	3e-05	0.000404	CbGpPWpGaD
Everolimus—Pruritus—Doxorubicin—sarcoma	2.99e-05	0.000257	CcSEcCtD
Everolimus—MTOR—Innate Immune System—JUN—sarcoma	2.96e-05	0.000399	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—sarcoma	2.94e-05	0.000396	CbGpPWpGaD
Everolimus—Vomiting—Epirubicin—sarcoma	2.91e-05	0.00025	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—KIT—sarcoma	2.9e-05	0.00039	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CXCR4—sarcoma	2.89e-05	0.00039	CbGpPWpGaD
Everolimus—Diarrhoea—Doxorubicin—sarcoma	2.89e-05	0.000249	CcSEcCtD
Everolimus—Rash—Epirubicin—sarcoma	2.88e-05	0.000248	CcSEcCtD
Everolimus—Dermatitis—Epirubicin—sarcoma	2.88e-05	0.000247	CcSEcCtD
Everolimus—Headache—Epirubicin—sarcoma	2.86e-05	0.000246	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—ATF1—sarcoma	2.86e-05	0.000386	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—sarcoma	2.81e-05	0.000379	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—sarcoma	2.8e-05	0.00024	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CREB1—sarcoma	2.76e-05	0.000371	CbGpPWpGaD
Everolimus—Nausea—Epirubicin—sarcoma	2.71e-05	0.000233	CcSEcCtD
Everolimus—Vomiting—Doxorubicin—sarcoma	2.69e-05	0.000231	CcSEcCtD
Everolimus—Rash—Doxorubicin—sarcoma	2.67e-05	0.000229	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—sarcoma	2.66e-05	0.000229	CcSEcCtD
Everolimus—MTOR—Innate Immune System—SRC—sarcoma	2.66e-05	0.000358	CbGpPWpGaD
Everolimus—Headache—Doxorubicin—sarcoma	2.65e-05	0.000228	CcSEcCtD
Everolimus—MTOR—Innate Immune System—NRAS—sarcoma	2.56e-05	0.000344	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—SRC—sarcoma	2.55e-05	0.000344	CbGpPWpGaD
Everolimus—FKBP1A—Disease—SRC—sarcoma	2.54e-05	0.000342	CbGpPWpGaD
Everolimus—MTOR—Immune System—KIT—sarcoma	2.52e-05	0.000339	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—sarcoma	2.51e-05	0.000216	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—NRAS—sarcoma	2.45e-05	0.000331	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NRAS—sarcoma	2.44e-05	0.000329	CbGpPWpGaD
Everolimus—MTOR—Immune System—CREB1—sarcoma	2.4e-05	0.000323	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—sarcoma	2.33e-05	0.000314	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—sarcoma	2.33e-05	0.000313	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MDM2—sarcoma	2.28e-05	0.000307	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MYC—sarcoma	2.28e-05	0.000307	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF1R—sarcoma	2.25e-05	0.000303	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—sarcoma	2.24e-05	0.000301	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—sarcoma	2.23e-05	0.0003	CbGpPWpGaD
Everolimus—MTOR—Disease—CREB1—sarcoma	2.21e-05	0.000298	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—KRAS—sarcoma	2.2e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO1—sarcoma	2.14e-05	0.000288	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFRB—sarcoma	2.13e-05	0.000287	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—KRAS—sarcoma	2.11e-05	0.000285	CbGpPWpGaD
Everolimus—FKBP1A—Disease—KRAS—sarcoma	2.1e-05	0.000283	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—PDGFRA—sarcoma	2.1e-05	0.000283	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IL2—sarcoma	2.04e-05	0.000275	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CCND1—sarcoma	1.99e-05	0.000268	CbGpPWpGaD
Everolimus—MTOR—Immune System—MDM2—sarcoma	1.98e-05	0.000267	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—JUN—sarcoma	1.98e-05	0.000267	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—sarcoma	1.97e-05	0.000265	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—HRAS—sarcoma	1.87e-05	0.000252	CbGpPWpGaD
Everolimus—MTOR—Disease—MDM2—sarcoma	1.83e-05	0.000247	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HRAS—sarcoma	1.8e-05	0.000242	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HRAS—sarcoma	1.79e-05	0.000241	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—SRC—sarcoma	1.78e-05	0.00024	CbGpPWpGaD
Everolimus—MTOR—Immune System—IL2—sarcoma	1.77e-05	0.000239	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KDR—sarcoma	1.77e-05	0.000238	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—sarcoma	1.73e-05	0.000233	CbGpPWpGaD
Everolimus—MTOR—Immune System—JUN—sarcoma	1.72e-05	0.000232	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—sarcoma	1.71e-05	0.000231	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NRAS—sarcoma	1.71e-05	0.000231	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—sarcoma	1.63e-05	0.000219	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MYC—sarcoma	1.59e-05	0.000215	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—sarcoma	1.58e-05	0.000213	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—sarcoma	1.56e-05	0.00021	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CREB1—sarcoma	1.55e-05	0.000209	CbGpPWpGaD
Everolimus—MTOR—Immune System—SRC—sarcoma	1.55e-05	0.000208	CbGpPWpGaD
Everolimus—MTOR—Immune System—NRAS—sarcoma	1.49e-05	0.000201	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KRAS—sarcoma	1.47e-05	0.000198	CbGpPWpGaD
Everolimus—MTOR—Disease—SRC—sarcoma	1.43e-05	0.000192	CbGpPWpGaD
Everolimus—MTOR—Disease—NRAS—sarcoma	1.37e-05	0.000185	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—sarcoma	1.36e-05	0.000183	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—sarcoma	1.31e-05	0.000176	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MDM2—sarcoma	1.28e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Immune System—KRAS—sarcoma	1.28e-05	0.000173	CbGpPWpGaD
Everolimus—MTOR—Disease—MYC—sarcoma	1.28e-05	0.000172	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—sarcoma	1.25e-05	0.000169	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HRAS—sarcoma	1.25e-05	0.000169	CbGpPWpGaD
Everolimus—MTOR—Disease—KRAS—sarcoma	1.18e-05	0.000159	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IL2—sarcoma	1.15e-05	0.000154	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—sarcoma	1.13e-05	0.000152	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—HBA1—sarcoma	1.12e-05	0.000151	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CCND1—sarcoma	1.12e-05	0.000151	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—JUN—sarcoma	1.12e-05	0.00015	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—sarcoma	1.11e-05	0.000149	CbGpPWpGaD
Everolimus—MTOR—Immune System—HRAS—sarcoma	1.09e-05	0.000147	CbGpPWpGaD
Everolimus—MTOR—Disease—HRAS—sarcoma	1.01e-05	0.000135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—SRC—sarcoma	1e-05	0.000135	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—sarcoma	9.74e-06	0.000131	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NRAS—sarcoma	9.62e-06	0.00013	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PLCG1—sarcoma	9.56e-06	0.000129	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MYC—sarcoma	8.96e-06	0.000121	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—sarcoma	8.77e-06	0.000118	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KRAS—sarcoma	8.28e-06	0.000112	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—sarcoma	7.36e-06	9.92e-05	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HRAS—sarcoma	7.04e-06	9.48e-05	CbGpPWpGaD
